C o r e C The Administrative Core (Core C) provides leadership and administrative support for the planning, coordination, implementation and ongoing review of the individual research projects, cores and program of clinical trials to be conducted under the proposed Program Project. To foster the scientific and clinical objectives ofthe individual projeds and the Program Project as a whole, this core conducts periodic meetings with the participating principal investigators to develop strategic plans and consensual decisions regarding program development and organizes periodic reviews of research progress and productivity by external scientific advisory committees. This Core also provides direction and coordination for the activities of the transplant program's integrated data management. The core also maintains and facilitates communication between investigators in the individual projects and cores through weekly conferences and research-in-progress presentations. Lastly, this Core provides fiscal management services for the projects and cores of the Program Project, and provides critical analytic support for the preparation of research progress reports and interim analyses of clinical trials as required by the IRB, NMDP, NIH and, as applicable the FDA.

Public Health Relevance

This Administrative Core provides scientific leadership and overall direction to the Program. This ensures appropriately frugal use of limited resources for maximal effect. This core also has and will continue to foster rapid translation of discoveries made in the Research Project into clinical trials and ultimate extension to the community.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA023766-34
Application #
8435577
Study Section
Special Emphasis Panel (ZCA1-RPRB-B (O1))
Project Start
1998-09-01
Project End
2018-03-31
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
34
Fiscal Year
2013
Total Cost
$188,390
Indirect Cost
$81,834
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Shah, Gunjan L; Moskowitz, Craig H (2018) Transplant strategies in relapsed/refractory Hodgkin lymphoma. Blood 131:1689-1697
Avanzi, Mauro P; Yeku, Oladapo; Li, Xinghuo et al. (2018) Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System. Cell Rep 23:2130-2141
Staffas, Anna; Burgos da Silva, Marina; Slingerland, Ann E et al. (2018) Nutritional Support from the Intestinal Microbiota Improves Hematopoietic Reconstitution after Bone Marrow Transplantation in Mice. Cell Host Microbe 23:447-457.e4
Velardi, Enrico; Tsai, Jennifer J; Radtke, Stefan et al. (2018) Suppression of luteinizing hormone enhances HSC recovery after hematopoietic injury. Nat Med 24:239-246
Moskowitz, Craig H (2018) Should all patients with HL who relapse after ASCT be considered for allogeneic SCT? A consult, yes; a transplant, not necessarily. Blood Adv 2:821-824
Kim, Seong Jin; Huang, Yao-Ting; Foldi, Julia et al. (2018) Cytomegalovirus resistance in CD34+ -selected hematopoietic cell transplant recipients. Transpl Infect Dis 20:e12881
Maslak, Peter G; Dao, Tao; Bernal, Yvette et al. (2018) Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. Blood Adv 2:224-234
DeFilipp, Zachariah; Peled, Jonathan U; Li, Shuli et al. (2018) Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity. Blood Adv 2:745-753
Haak, Bastiaan W; Littmann, Eric R; Chaubard, Jean-Luc et al. (2018) Impact of gut colonization with butyrate-producing microbiota on respiratory viral infection following allo-HCT. Blood 131:2978-2986
Boudreau, Jeanette E; Hsu, Katharine C (2018) Natural Killer Cell Education and the Response to Infection and Cancer Therapy: Stay Tuned. Trends Immunol 39:222-239

Showing the most recent 10 out of 452 publications